Physician profile
Maile E Parker
NPI 1366880486
$7,172.69
in general payments reported to CMS, 2019-2025
12 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,102 · 2020: $1,395 · 2021: $93.51 · 2022: $418 · 2023: $8.50 · 2024: $1,789 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106 · Travel and Lodging: $1,051 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.84 |
| Travel and Lodging | $1,050.51 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,764.39 | 2019-2025 | Da Vinci Surgical System |
| Davol INC. | $150.15 | 2024-2025 | Phasix Mesh, Arista |
| Boston Scientific Corporation | $36.95 | 2020-2021 | |
| Braintree Laboratories, INC. | $30.76 | 2019-2021 | |
| Innovation Technologies INC | $30.11 | 2022 | |
| Smith+Nephew, INC. | $27.00 | 2025 | Stravix Pl |
| Baxter Healthcare | $25.58 | 2025 | Perclot |
| Solventum Corporation | $25.43 | 2024 | Prevena, V.A.C. Veraflo |
| Aimmune Therapeutics, INC. | $23.60 | 2025 | Zenpep |
| Heron Therapeutics, INC. | $21.97 | 2024 | Zynrelef |
| Intercept Pharmaceuticals, INC. | $21.07 | 2024 | |
| Kci USA, INC. | $15.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maile Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.